TY - JOUR
T1 - Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas
AU - Miyatake, Shin Ichi
AU - Kawabata, Shinji
AU - Yokoyama, Kunio
AU - Kuroiwa, Toshihiko
AU - Michiue, Hiroyuki
AU - Sakurai, Yoshinori
AU - Kumada, Hiroaki
AU - Suzuki, Minoru
AU - Maruhashi, Akira
AU - Kirihata, Mitsunori
AU - Ono, Koji
PY - 2009
Y1 - 2009
N2 - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.
AB - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.
KW - BNCT
KW - BPA-PET
KW - GBM
KW - MG
KW - RPA
UR - http://www.scopus.com/inward/record.url?scp=57349087805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349087805&partnerID=8YFLogxK
U2 - 10.1007/s11060-008-9699-x
DO - 10.1007/s11060-008-9699-x
M3 - Article
C2 - 18813875
AN - SCOPUS:57349087805
SN - 0167-594X
VL - 91
SP - 199
EP - 206
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 2
ER -
